The company is still riding the momentum of its technology being included in the 2021 American College of Cardiology/American Heart Association chest pain guidelines.

Radiology makes up the vast majority of FDA-cleared AI algorithms, but with minimal or no reimbursement, hospital administrators may ask whether AI’s value justifies its expense.

Overall, cardiologists made corrections to 16.8% of AI-generated assessments and 27.2% of sonographer assessments.

According to data submitted to the FDA, the platform has been linked to an accuracy of 90%, sensitivity of 87.8% and specificity of 83%.

The new study, presented at the AHA Scientific Sessions 2022 conference in Chicago, focused on data from more than 2,000 patients. 

With healthcare providers under continuing pressure to provide better care at lower costs, remote cardiac monitoring devices are becoming popular and valuable patient care tools, fueling U.S. market growth expected to top more than 25 percent between 2011 and 2016.[1]  The devices enable cardiologists to monitor patients for extended periods of time outside the costly hospital environment, improving their ability to identify problems and provide early intervention that can support better outcomes and reduce the need for expensive future care.